<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399035</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00051</org_study_id>
    <secondary_id>EUDRACT No 2006-001194-14</secondary_id>
    <secondary_id>HORIZON II</secondary_id>
    <nct_id>NCT00399035</nct_id>
  </id_info>
  <brief_title>Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer</brief_title>
  <acronym>HORIZON II</acronym>
  <official_title>A Randomised, Double-blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN™) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Cediranib when added to chemotherapy is more
      effective than chemotherapy alone in prolonging life expectancy and slowing disease
      progression in patients with previously untreated metastatic colorectal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.</time_frame>
    <description>RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression [non-PD]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
    <description>Number of months from randomisation to the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
    <description>Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Percentage Change in Tumour Size</measure>
    <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
    <description>Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Treatment period from initial response up until data cut-off date of 21/03/10</time_frame>
    <description>Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Resection of Liver Metastases</measure>
    <time_frame>Post-randomisation until end of study</time_frame>
    <description>Number of patients undergoing liver resection, based on patients with liver disease at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Wound Healing Complications</measure>
    <time_frame>Post-randomisation until end of study</time_frame>
    <description>Number of days from post-randomisation surgery until wound healing complications</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1254</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOX + placebo Cediranib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FOLFOX + placebo Cediranib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xelox + placebo Cediranib</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Xelox + placebo Cediranib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX + Cediranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFOX + Cediranib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX + Cediranib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX + Cediranib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>FOLFOX + Cediranib</arm_group_label>
    <arm_group_label>XELOX + Cediranib</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>RECENTIN™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>FOLFOX + placebo Cediranib</arm_group_label>
    <arm_group_label>FOLFOX + Cediranib</arm_group_label>
    <other_name>Other Names:</other_name>
    <other_name>5-FU</other_name>
    <other_name>Drug: Leucovorin (in FOLFOX)</other_name>
    <other_name>intravenous infusion</other_name>
    <other_name>Drug: Oxaliplatin (in FOLFOX)</other_name>
    <other_name>Eloxatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX (Capecitabine and Oxaliplatin)</intervention_name>
    <description>intravenous oxaliplatin 130 mg/ m^2(day 1) followed by oral capecitabine 1,000 mg/ m^2twice daily (day 1 to day 15)</description>
    <arm_group_label>Xelox + placebo Cediranib</arm_group_label>
    <arm_group_label>XELOX + Cediranib</arm_group_label>
    <other_name>Xeloda® + Eloxatin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib Placebo</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>FOLFOX + placebo Cediranib</arm_group_label>
    <arm_group_label>Xelox + placebo Cediranib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written Informed Consent

          -  Carcinoma of the colon or rectum

          -  One or more measurable lesions

        Exclusion Criteria:

          -  Adjuvant/neoadjuvant therapy within 6-12 months of study entry

          -  Untreated unstable brain or meningeal metastases

          -  Specific laboratory ranges

          -  Specific cardiovascular problems

          -  Participation in other trials within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Robertson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires City</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Capital Federal</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Resistencia</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashford</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Camperdown</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hornsby</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waratah</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wodonga</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jaú</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo André</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vratza</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ChongQing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fuzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cheb</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jicin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jihlava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pribram - Zdabor</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sumperk</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goslar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trivandrum</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cebu City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Locarno</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>China</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=424&amp;filename=CSR-D8480C00051.pdf</url>
    <description>CSR-D8480C00051.pdf</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <results_first_submitted>March 29, 2012</results_first_submitted>
  <results_first_submitted_qc>September 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 30, 2012</results_first_posted>
  <disposition_first_submitted>April 6, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>April 6, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 12, 2011</disposition_first_posted>
  <last_update_submitted>November 7, 2016</last_update_submitted>
  <last_update_submitted_qc>November 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Cediranib</keyword>
  <keyword>RECENTIN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomised=full analysis set: Cediranib 20mg=502, Placebo=358; Safety set: Cediranib 20mg=500, Cediranib 30mg=214, Placebo=358</recruitment_details>
      <pre_assignment_details>Cediranib 30 mg discontinued following Phase II, Cediranib 20 mg chosen dose for comparing with Placebo.
1254 patients enrolled to the study, 1076 recieved study treatment; 2 patients lost for Cediranib 20 mg/day, and 2 patients lost for Cediranib 30 mg/day.The 4 patients that didn't receive drug are intentionally included.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cediranib 20 mg/Day</title>
          <description>[Cediranib 20mg/day+FOLFOX/XELOX].2 FOLFOX regimens were chosen:FOLFOX4 or mFOLFOX6(repeated every 2 weeks.FOLFOX4:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 200mg/m2(or equivalent folinic acid preparation) by iv infusion over 2h on Day1 and Day2;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1 and Day2;5-FU 600 mg/m2 immediately after the 5-FU bolus dosed by continuous iv infusion over 22h on Day1 and Day2.mFOLFOX6:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 400mg/m2(or equivalent folinic acid preparation)dosed iv over 2h on Day1;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1,followed immediately by 5-FU 2400mg/m2 dosed by continuous iv infusion over 46h.XELOX:The XELOX regimen was to be repeated every 3 weeks:oxaliplatin 130mg/m2 dosed by iv infusion over 2h on Day1;capecitabine 1000mg/m2 orally twice daily on Days1 to 14.</description>
        </group>
        <group group_id="P2">
          <title>Cediranib 30 mg/Day</title>
          <description>[Cediranib 30mg/day+FOLFOX/XELOX].2 FOLFOX regimens were chosen:FOLFOX4 or mFOLFOX6(repeated every 2 weeks.FOLFOX4:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 200mg/m2(or equivalent folinic acid preparation) by iv infusion over 2h on Day1 and Day2;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1 and Day2;5-FU 600 mg/m2 immediately after the 5-FU bolus dosed by continuous iv infusion over 22h on Day1 and Day2.mFOLFOX6:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 400mg/m2(or equivalent folinic acid preparation)dosed iv over 2h on Day1;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1,followed immediately by 5-FU 2400mg/m2 dosed by continuous iv infusion over 46h.XELOX:The XELOX regimen was to be repeated every 3 weeks:oxaliplatin 130mg/m2 dosed by iv infusion over 2h on Day1;capecitabine 1000mg/m2 orally twice daily on Days1 to 14.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>[Placebo +FOLFOX/XELOX].2 FOLFOX regimens were chosen:FOLFOX4 or mFOLFOX6(repeated every 2 weeks.FOLFOX4:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 200mg/m2(or equivalent folinic acid preparation) by iv infusion over 2h on Day1 and Day2;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1 and Day2;5-FU 600 mg/m2 immediately after the 5-FU bolus dosed by continuous iv infusion over 22h on Day1 and Day2.mFOLFOX6:oxaliplatin 85mg/m2 dosed by iv infusion over 2h on Day1;leucovorin 400mg/m2(or equivalent folinic acid preparation)dosed iv over 2h on Day1;5-FU 400mg/m2 iv bolus immediately after completion of the oxaliplatin/leucovorin infusion on Day1,followed immediately by 5-FU 2400mg/m2 dosed by continuous iv infusion over 46h.XELOX:The XELOX regimen was to be repeated every 3 weeks:oxaliplatin 130mg/m2 dosed by iv infusion over 2h on Day1;capecitabine 1000mg/m2 orally twice daily on Days1 to 14.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="502"/>
                <participants group_id="P2" count="216"/>
                <participants group_id="P3" count="358"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="58"/>
                <participants group_id="P3" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="158"/>
                <participants group_id="P3" count="252"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="141"/>
                <participants group_id="P3" count="234"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrolment/eligib not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Severe non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cediranib 20 mg</title>
          <description>Cediranib 20 mg + FOLFOX/XELOX</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo + FOLFOX/XELOX</description>
        </group>
        <group group_id="B3">
          <title>Cediranib 30 mg</title>
          <description>Cediranib 30 mg/day + FOLFOX/XELOX</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="502"/>
            <count group_id="B2" value="358"/>
            <count group_id="B3" value="216"/>
            <count group_id="B4" value="1076"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at informed consent</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.8" spread="11.14"/>
                    <measurement group_id="B2" value="57.2" spread="11.63"/>
                    <measurement group_id="B3" value="59.4" spread="10.69"/>
                    <measurement group_id="B4" value="57.6" spread="11.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender at informed consent</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="146"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="442"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="299"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="123"/>
                    <measurement group_id="B4" value="634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival</title>
        <description>RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression [non-PD]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.</description>
        <time_frame>RECIST assessed at baseline every 6 weeks through to week 24 and 12 week thereafter through to progression or data cut off date of 21/03/10 whichever was earliest.</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation.The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>RECIST criteria defined as follows: Target lesions Complete Response (CR) Disappearance of all target lesions Partial Response (PR) At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD.Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Non-target lesions Complete Response (CR) Disappearance of all non-target lesions Non-Complete Response (non-CR/Non- Progression [non-PD]) Persistence of one or more non-target lesion or/and maintenance of tumour marker level above the normal limits. Progression (PD) Unequivocal progression of existing nontarget lesions.</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation.The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.5" upper_limit="12.1"/>
                    <measurement group_id="O2" value="8.2" lower_limit="4.1" upper_limit="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Number of months from randomisation to the date of death from any cause</description>
        <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of months from randomisation to the date of death from any cause</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="11.0" upper_limit="36.1"/>
                    <measurement group_id="O2" value="18.9" lower_limit="11.0" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi</description>
        <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>Objective tumour response(defined as a confirmed response of CR or PR).The definition for a confirmed response was met when an initial RECIST response of PR/CR was confirmed at the next scheduled visit as a PR/CR according to an evaluable assessment.Intervening assessments of non-evaluable or stable disease were allowable as long as the initial RECIST response was confirmed.RECIST criteria defined as follows: Target lesions Complete Response(CR)Disappearance of all target lesions Partial Response (PR).At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. Progressive Disease (PD) At least a 20% increase in the sum of LD of target lesions taking as references the smallest sum LD recorded (either at baseline or at previous assessment since treatment began).Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.Non-target lesions Complete Response (CR) Disappearance of all non-target lesi</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="502"/>
                <count group_id="O2" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="254"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Percentage Change in Tumour Size</title>
        <description>Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions</description>
        <time_frame>Baseline through to date of death upto and including data cut off date of 21/03/10</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Best Percentage Change in Tumour Size</title>
          <description>Maximum percentage reduction or minimum percentage increase in tumour size where size is the sum of the longest diameters of the target lesions</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Percentage [change in tumour size (mm) ]</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="474"/>
                <count group_id="O2" value="339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.49" spread="28.139"/>
                    <measurement group_id="O2" value="-40.61" spread="31.992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response</title>
        <description>Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.</description>
        <time_frame>Treatment period from initial response up until data cut-off date of 21/03/10</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response</title>
          <description>Based on RECIST measurements taken throughout the study and best objective tumour response at the defined analysis cut-off point. Measured from the time the criteria for CR/PR are first met (whichever is recorded first) until the patient progresses or dies.</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.9" upper_limit="12.7"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.8" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Resection of Liver Metastases</title>
        <description>Number of patients undergoing liver resection, based on patients with liver disease at baseline</description>
        <time_frame>Post-randomisation until end of study</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Resection of Liver Metastases</title>
          <description>Number of patients undergoing liver resection, based on patients with liver disease at baseline</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="387"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Wound Healing Complications</title>
        <description>Number of days from post-randomisation surgery until wound healing complications</description>
        <time_frame>Post-randomisation until end of study</time_frame>
        <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Cediranib 20 mg</title>
            <description>Cediranib 20 mg/day + FOLFOX/XELOX</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo + FOLFOX/XELOX</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Wound Healing Complications</title>
          <description>Number of days from post-randomisation surgery until wound healing complications</description>
          <population>Two cediranib doses (20 mg and 30 mg) were initially included in this study; however, it was intended that one dose would be selected for continuation. The decision was taken to continue with cediranib 20 mg. All efficacy analyses compared cediranib 20mg to placebo. No statistical analyses were performed on the 30mg group.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" lower_limit="1" upper_limit="93"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cediranib 30mg</title>
          <description>Cediranib 30mg/day + Folfox/Xelox</description>
        </group>
        <group group_id="E2">
          <title>Cediranib 20mg</title>
          <description>Cediranib 20mg/day + Folfox/Xelox</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo + Folfox/Xelox</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Coombs Positive Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Acute Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Retinal Vein Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Anal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colonic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ileitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intestinal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lower Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Mesenteric Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Proctocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rectal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Varices Oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Infusion Site Irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hepatorenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Amoebic Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Blastocystis Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Campylobacter Intestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Catheter Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Central Line Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Colostomy Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Infected Epidermal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Scrotal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Comminuted Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Stoma Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peroneal Nerve Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Postoperative Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Stent Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ureteric Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin Conjugated Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hyperammonaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Benign Neoplasm Of Spinal Cord</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Penis Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Central Nervous System Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nervous System Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neurological Symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Reversible Posterior Leukoencephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Personality Change Due To A General Medical Condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Ureteric Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Female Genital Tract Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dysaesthesia Pharynx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pulmonary Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Aortic Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vena Cava Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="209" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="485" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="341" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="39" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="346" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="165" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="256" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="169" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="126" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="134" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="125" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Palmar-Plantar Erythrodysaesthesia Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="123" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Skin Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="358"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="214"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="500"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="358"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

